United Therapeutics Corporation (UTHR)
UTHR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$543.40
-1.22% on the day
Market cap
$23.3B
Large cap
Revenue · 2025
$3.2B
+10.6% on 2024
Net income · 2025
$1.3B
41.9% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | UTHR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 1999 |
| SEC CIK | 0001082554 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.2B |
| Net income | $1.3B |
| Operating income | $1.5B |
| Net margin | 41.9% |
| Operating margin | 46.9% |
| Revenue growth | +10.6% |
| Cash | $1.6B |
| Total assets | $7.9B |
| P/E (computed) | 17.5× |
| P/S (computed) | 7.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report FORM 8-K | 8-K | 2026-10-14 |
| Latest proxy DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.6% |
| 1 month | +8.2% |
| 3 months | +2.4% |
| Year to date | +11.2% |
| 1 year | +23.1% |
| From 52-week high | -9.2% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GMAB | Genmab A/S ADS | $36.57 | -2.14% | $22.8B |
| ROIV | Roivant Sciences Ltd. Common Shares | $33.35 | -3.58% | $24.1B |
| INSM | Insmed Incorporated | $96.79 | -1.80% | $21.1B |
| VTRS | Viatris Inc. | $17.25 | -1.65% | $19.8B |
| ALNY | Alnylam Pharmaceuticals Inc. | $223.82 | -1.41% | $29.9B |
| ZTS | Zoetis Inc. | $74.30 | -1.78% | $30.7B |
| RPRX | Royalty Pharma plc Class A Ordinary Shares | $56.57 | -2.09% | $32.5B |
| ASND | Ascendis Pharma A/S Ordinary Share | $223.21 | -1.67% | $14.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier